Not Signed In - Glivec Improves Long-term Survival Prospects For Chronic Myeloid Leukaemia Patients
Mon, 26 Dec 2005 09:00 PM EST
... Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study... click link for more info. ...
Related Topics
- Long Term Care
- Acute Care
- Leukemia
- Long Term Care/ltc
- Nursing Home Care
- Chronic Fatigue Syndrome
- Pain - Chronic
- Chronic Pain
- Disabilities
- Chronic Diseases
- Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
- Carbon Monoxide Poisoning
- Adult Acute Myeloid Leukemia
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Kidney Transplantation
- Smoking Cessation and Continued Risk in Cancer Patients
- Chronic Lymphocytic Leukemia
- Leukemia, Chronic Lymphocytic
- Inhalants
email this page
print this page
bookmark this page
feedback on this page
